Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00040521
Status:
COMPLETED
Last Update Posted:
2013-02-08
First Post:
2002-06-27
Brief Title:
Study Evaluating rhIL-11 in Active Crohns Disease
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Placebo-Controlled Dose-Ranging Study of Orally Administered Recombinant Human Interleukin-11 rhIL-11 for the Treatment of Patients With Active Crohns Disease
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the activity of multiple doses of oral rhIL-11 in patients with active Crohns disease Crohns Disease Activity Index CDAI score from 220-400
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B2491021 | OTHER | Pfizer | None |